Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Emopwering people to improve their musculoskeletal health through exercise. TrackActive is a physical health app that assesses a person's conditions, health and habits and delivers a personalised programme consisting of advice and exercises that adapt as the person progresses. The app is developed using rehabilitative exercise data, clinical algorithms and AI. The app can be used by organisations to view anonymised information on the health of their employees or customers and is distributed via public health, corporate and insurance partners.
TrackActive will be monetised via the aforementioned partners, who will pay an ongoing monthly subscription from £25 per month. This figure may increase depending on the health practitioners using the service. TrackActive's content, such as articles, video and images, can also be licensed to partners. Funds will be allocated towards developing the product further, with the inclusion of an Android version, admin dashboards, evidence-based content and regular updates to the app.
days to go:
Expired
investment:
£253,598
With new MiFID II regulations introduced in January, Hiddensee provides independent investment research mainly on forensic accounting and corporate governance. Analysts will search for inconsistencies and anomalies in the valuation of UK listed mid-cap and smaller companies and publish their reports to assist investors in deciding whether to buy or sell shares.
days to go:
Expired
investment:
£143,097
Cuckooz Nest is London’s pay-as-you-go nursery with an integrated workspace for the modern working parent. With the ability to support both individuals and bigger businesses, it bridges the gap between work and life by providing an accessible, flexible, affordable and scalable childcare. It has already helped over 100 families to attain a greater work-life balance. Cuckooz Nest has also been shortlisted for many awards such as Best Workspace, Nursery Innovation Award, and The People’s Choice Award. With the same purpose to provide creative childcare solutions, this company has partnered with Manny & Me, a London-based agency, to ensure the delivery of the highest quality of staff and educational programming.Cuckooz Nest, with the proceeds, is planning to set up a much larger site to help a substantial number of men and women manage their work and family.
days to go:
Expired
investment:
£131,650
Intellibonds is a platform that utilizes AI to enhance fixed-income investing. It assists institutional investors in reducing expenses through intelligent automation and converting data into actionable insights. Intellibonds' virtual AI assistants work alongside your investment professionals, enhancing efficiency and decision-making.
days to go:
Expired
investment:
£208,713
DiPocket has created a mobile banking app to make instant international bank transfers, with low foreign exchange rates quick and easy. The app is a simple solution to collect and spend money with friends, and it comes with a range of mastercards so it can be used anywhere.
days to go:
Expired
investment:
£157,275
Rnwl is aiming to be the first ever over-the-top insurance platform. The company asserts that conventional insurance companies rely on a lead generation business model that is archaic and inefficient. These result in a customer's insurance options becoming an expensive and time-consuming affair. Rnwl is endeavouring to simplify this. Users can enter their credentials and requirements on the Rnwl website. The company will analyse the market and suggest the best deals for the user. Rnwl has been accepted into the Financial Conduct Authority (FCA's) Innovation Hub. It will use 74% of the investment in human resource, 14% in marketing, and 12% as operational costs.
days to go:
Expired
investment:
£450,366
